[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100656989":3},{"organization":4,"outcomesModule":7,"designInfo":34,"detailedDescription":37,"studyPopulation":37,"armGroups":44,"interventions":58,"overallOfficials":76,"centralContacts":81,"locations":91,"responsibleParty":139,"collaborators":37,"id":141,"slug":142,"hasResults":143,"nctId":144,"briefTitle":145,"officialTitle":145,"acronym":37,"eligibilityCriteria":146,"healthyVolunteers":143,"sex":147,"minAge":148,"maxAge":149,"enrollmentInfo":150,"targetDuration":37,"studyType":153,"phases":154,"briefSummary":156,"conditions":157,"keywords":161,"overallStatus":164,"whyStopped":37,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":174},{"fullName":5,"class":6},"Beijing Tiantan Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":29},[9],{"measure":10,"description":11,"timeFrame":12},"Improvement rate of the CSIT score at 4 weeks","Improvement rate of the CSIT score at 4 weeks.The olfactory identification test is the Chinese Smell Identification Test (CSIT), developed by the Human Olfaction Laboratory, Institute of Psychology, Chinese Academy of Sciences, based on the Chinese population. It contains 40 odor items familiar to the Chinese population and has a 6-month test-retest reliability of 0.92.If the CSIT score improves by 4 points or more, this indicates an improvement in olfactory function.","From enrollment to the end of treatment at 4 weeks",[14,18,22,26],{"measure":15,"description":16,"timeFrame":17},"Improvement rate of the CSIT score at 12 weeks","Rate of improvement in olfactory identification test scores after 12 weeks,The olfactory identification test is the Chinese Smell Identification Test (CSIT), developed by the Human Olfaction Laboratory, Institute of Psychology, Chinese Academy of Sciences, based on the Chinese population. It contains 40 odor items familiar to the Chinese population and has a 6-month test-retest reliability of 0.92.If the CSIT score improves by 4 points or more, this indicates an improvement in olfactory function.","at 12 weeks after enrollment",{"measure":19,"description":20,"timeFrame":21},"olfactory threshold scores","It measures the lowest concentration level that the patient can perceive, assessing sensitivity in detecting odors. It targets the peripheral olfactory nerves. It includes 20 concentration-graded odor sticks (of the same odor) and a baseline odor stick (nearly odorless). The patient smells one graded odor stick and one baseline odor stick sequentially and compares which odor is stronger.","From enrollment to the end of treatment at 4 weeks；12 weeks after enrollment",{"measure":23,"description":24,"timeFrame":25},"subjective olfactory function","The visual analogue scale (VAS, 0-100) in the olfactory disorder scale was used to rate the severity of olfactory loss, where 0 indicates normal olfaction and 100 indicates complete loss of smell. According to other published studies, the severity of olfactory loss was categorized as mild (0-30), moderate (31-70), and severe (\\>70).","From enrollment to the end of treatment at 8 weeks;12 weeks after enrollment",{"measure":27,"description":28,"timeFrame":25},"Emotional and psychological assessment","Emotional and psychological assessment will be conducted using the Hamilton Anxiety Scale (HAMA), the 17-item Hamilton Depression Scale (HAMD17), the Generalized Anxiety Disorder 7-item scale (GAD-7), and the Patient Health Questionnaire-9 (PHQ-9) to evaluate patients' emotional and psychological status.",[30],{"measure":31,"description":32,"timeFrame":33},"Adverse events","Adverse events within 12 weeks after randomization, such as infection, pain, and other acupuncture-related complications in the Traditional Chinese Medicine Department; major adverse events will be reported until the end of the study.","From enrollment to the end of observation at 12 weeks",{"allocation":35,"interventionModel":36,"interventionModelDescription":37,"primaryPurpose":38,"observationalModel":37,"timePerspective":37,"maskingInfo":39},"RANDOMIZED","PARALLEL",null,"TREATMENT",{"masking":40,"maskingDescription":37,"whoMasked":41},"DOUBLE",[42,43],"PARTICIPANT","OUTCOMES_ASSESSOR",[45,52],{"label":46,"type":47,"description":48,"interventionNames":49},"Treatment arm","ACTIVE_COMPARATOR","The treatment group includes two interventions: acupuncture and a steroid placebo (prednisone placebo).\n\nAcupoint selection: Fengchi (GB20, bilateral, quick needling), Jingbailao (bilateral, quick needling), Dazhuipang (bilateral, quick needling); Shenting (DU24), Baihui (DU20), Yingxiang penetrating Bitong (bilateral), Quanliao penetrating Bitong (bilateral), Hegu (LI4, bilateral), Wailaogong (bilateral), Zusanli (ST36, bilateral), Taichong (LR3, bilateral).\n\nProcedure: First, the patient sits upright. Quick needling (without retaining needles) is performed at Fengchi, Jingbailao, and Dazhuipang. Then, the patient assumes a supine position. Needles are inserted Shenting, Baihui, etc.while deep needling is performed at Yingxiang penetrating Bitong, Quanliao penetrating Bitong, Hegu, and Zusanli. After achieving deqi (needle sensation), the needles are retained for 20 minutes.\n\nCourse: 3×\u002Fweek for 4 weeks (12 sessions). Oral prednisone placebo at same dose\u002Fduration as control group.",[50,51],"Other: Acupuncture","Drug: Oral Prednisone placebo",{"label":53,"type":47,"description":54,"interventionNames":55},"control arm","Medication: Oral prednisone given as a short-term course (4 weeks). Dosage and tapering schedule: Week 1: 30 mg\u002Fd; Week 2: 15 mg\u002Fd; Week 3: 10 mg\u002Fd; Week 4: 5 mg\u002Fd, then discontinued after 4 weeks.\n\nSham acupuncture: Park sham acupuncture device (placebo needle) is used. The acupoint selection and operation sites are the same as those in the treatment group. After routine disinfection, the needle holder is applied to the acupoint, and the needle is inserted into the holder without penetrating the skin, and retained for 20 minutes. The treatment course is the same as the treatment group (3 times per week for 4 weeks).",[56,57],"Drug: Corticosteroid therapy","Other: sham acupuncture",[59,63,68,72],{"type":6,"name":60,"description":61,"armGroupLabels":62,"otherNames":37},"Acupuncture","Acupoint selection:\n\nFengchi (GB20, bilateral, quick needling), Jingbailao (bilateral, quick needling), Dazhuipang (bilateral, quick needling); Shenting (DU24), Baihui (DU20), Yingxiang penetrating Bitong (bilateral), Quanliao penetrating Bitong (bilateral), Hegu (LI4, bilateral), Wailaogong (bilateral), Zusanli (ST36, bilateral), Taichong (LR3, bilateral).\n\nProcedure:\n\nThe patient is first seated upright. Quick needling (without needle retention) is performed at Fengchi, Jingbailao, and Dazhuipang. Then the patient assumes a supine position. Needles are inserted at Shenting, Baihui, Wailaogong, and Taichong, while deep needling is applied at Yingxiang penetrating Bitong, Quanliao penetrating Bitong, Hegu, and Zusanli. After achieving deqi (needle sensation), the needles are retained for 20 minutes.\n\nCourse of treatment:\n\nAcupuncture is given 3 times per week for 4 weeks (total 12 sessions)",[46],{"type":64,"name":65,"description":66,"armGroupLabels":67,"otherNames":37},"DRUG","Corticosteroid therapy","Oral prednisone given as a short-term course (4 weeks). Dosage and tapering schedule: Week 1: 30 mg\u002Fd; Week 2: 15 mg\u002Fd; Week 3: 10 mg\u002Fd; Week 4: 5 mg\u002Fd, then discontinued after 4 weeks.",[53],{"type":6,"name":69,"description":70,"armGroupLabels":71,"otherNames":37},"sham acupuncture","Sham acupuncture: Park sham acupuncture device (placebo needle) is used. The acupoint selection and operation sites are the same as those in the treatment group. After routine disinfection, the needle holder is applied to the acupoint, and the needle is inserted into the holder without penetrating the skin, and retained for 20 minutes. The treatment course is the same as the treatment group (3 times per week for 4 weeks).",[53],{"type":64,"name":73,"description":74,"armGroupLabels":75,"otherNames":37},"Oral Prednisone placebo","The placebo tablets were manufactured to be identical in appearance (color, size, shape) and taste to the active prednisone tablets, ensuring effective blinding. Participants received the placebo orally according to the same tapering regimen as the control group: 30 mg\u002Fday (as equivalent tablet count) for week 1, 15 mg\u002Fday for week 2, 10 mg\u002Fday for week 3, and 5 mg\u002Fday for week 4, after which the medication was discontinued. The total course lasted 4 weeks, matching the duration of both the active prednisone therapy and the acupuncture sessions.",[46],[77],{"name":78,"affiliation":79,"role":80},"Huanqin Li","Beijing Tiantan Hosital","STUDY_CHAIR",[82,87],{"name":83,"role":84,"phone":85,"phoneExt":37,"email":86},"Huanqin Li, Doctor","CONTACT","0086+13521663936","hqin_li@163.com",{"name":88,"role":84,"phone":89,"phoneExt":37,"email":90},"Ruotong Zhao, Master","0086+17701054857","3380884776@qq.com",[92,108],{"facility":5,"status":37,"city":93,"state":94,"zip":95,"country":96,"countryCode":97,"cosmosGeoPoint":98,"geoPoint":103,"contacts":104},"Beijing","Beijing Municipality","100070","China","CN",{"type":99,"coordinates":100},"Point",[101,102],116.39723,39.9075,{"lat":102,"lon":101},[105],{"name":106,"role":84,"phone":107,"phoneExt":37,"email":86},"Li Huanqin Li","13521663936",{"facility":5,"status":37,"city":93,"state":94,"zip":95,"country":96,"countryCode":97,"cosmosGeoPoint":109,"geoPoint":111,"contacts":112},{"type":99,"coordinates":110},[101,102],{"lat":102,"lon":101},[113,114,116,119,121,123,125,127,129,131,133,135,137],{"name":78,"role":84,"phone":85,"phoneExt":37,"email":86},{"name":78,"role":115,"phone":37,"phoneExt":37,"email":37},"PRINCIPAL_INVESTIGATOR",{"name":117,"role":118,"phone":37,"phoneExt":37,"email":37},"Weiming Liu","SUB_INVESTIGATOR",{"name":120,"role":118,"phone":37,"phoneExt":37,"email":37},"Hao Shen",{"name":122,"role":118,"phone":37,"phoneExt":37,"email":37},"Ruotong Zhao",{"name":124,"role":118,"phone":37,"phoneExt":37,"email":37},"Yunfei Li",{"name":126,"role":118,"phone":37,"phoneExt":37,"email":37},"Qian Liu",{"name":128,"role":118,"phone":37,"phoneExt":37,"email":37},"Xiaoyu Yan",{"name":130,"role":118,"phone":37,"phoneExt":37,"email":37},"Mingxing Zhang",{"name":132,"role":118,"phone":37,"phoneExt":37,"email":37},"Mingyang Cao",{"name":134,"role":118,"phone":37,"phoneExt":37,"email":37},"Keren He",{"name":136,"role":118,"phone":37,"phoneExt":37,"email":37},"Yukun Liang",{"name":138,"role":118,"phone":37,"phoneExt":37,"email":37},"Jincun Lai",{"type":140,"investigatorFullName":37,"investigatorTitle":37,"investigatorAffiliation":37,"oldNameTitle":37,"oldOrganization":37},"SPONSOR","100656989","acupuncture-for-post-traumatic-olfactory-dysfunction-a-randomized-controlled-trial-100656989",false,"NCT07834047","Acupuncture for Post-traumatic Olfactory Dysfunction: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients with post-traumatic olfactory dysfunction who meet the diagnostic criteria;\n* Aged 18-60 years;\n* Subjects who have given informed consent and voluntarily participate and sign the informed consent form;\n* Have not received acupuncture treatment, olfactory disorder-related medications (such as intranasal corticosteroids or oral drugs), or olfactory training within the past 1 month;\n* Are in a stable post-traumatic condition without severe complications, and are able to cooperate with diagnosis, treatment, and evaluation.\n\nExclusion Criteria:\n\n* Patients with a clear history of viral infection or exposure to irritant substances prior to the onset of olfactory dysfunction;\n* History of nasopharyngeal tumor, or presence of active nasal diseases (sinusitis, nasal polyposis, atrophic rhinitis, allergy), as well as severe nasal obstruction caused by nasal stenosis or deformity;\n* History of chemotherapy or treatment with estrogen inhibitors (aromatase inhibitors), or prior use of medications known to be harmful to olfactory function before the onset of olfactory dysfunction;\n* Patients with cognitive impairment and neurodegenerative diseases (Alzheimer's disease and Parkinson's disease), or severe psychiatric disorders (e.g., schizophrenia, bipolar disorder, olfactory hallucinations);\n* Current use of medications that may affect olfaction (e.g., antidepressants and antihistamines);\n* Allergy to prednisone;\n* Pregnant or lactating women.","ALL","18 Years","60 Years",{"count":151,"type":152},84,"ESTIMATED","INTERVENTIONAL",[155],"NA","The goal of this clinical trial is to learn if acupuncture based on the \"Form-Qi-Spirit\" theory works to treat post-traumatic olfactory dysfunction in adults. It will also learn about the safety of this acupuncture treatment.\n\nThe main questions it aims to answer are:\n\nIs the efficacy of 4-week acupuncture treatment superior to 4-week steroid treatment for post-traumatic olfactory dysfunction?\n\nWhat medical problems or side effects do participants have when receiving acupuncture?\n\nResearchers will compare real acupuncture plus a placebo (a look-alike pill with no active drug) to sham acupuncture (non-penetrating placebo needles) plus low-dose oral steroids (prednisone) - to see if the real acupuncture strategy works better than the steroid strategy for post-traumatic olfactory dysfunction.\n\nParticipants will:\n\nReceive real acupuncture + placebo pills, OR sham acupuncture + low-dose prednisone, for 4 weeks\n\nUndergo acupuncture\u002Fsham sessions 3 times per week (12 sessions in total)\n\nTake the assigned pills daily (with tapering doses over 4 weeks)\n\nVisit the clinic for smell tests, psychological assessments, and safety checks at baseline, at 4 weeks (end of treatment), and at 12 weeks (8 weeks after treatment ends)\n\nLet me know if you need a more detailed version or any adjustments.",[158,159,160],"Post-traumatic Olfactory Dysfunction","Traumatic Brain Injury","Olfactory Dysfunction",[158,162,163,160,159],"PTOD","acupuncture","NOT_YET_RECRUITING","2026-09-17",{"date":167,"type":168},"2026-09-22","ACTUAL",{"date":170,"type":152},"2026-09-15",{"date":172,"type":152},"2028-08-31",{"name":5,"class":6},2]